title: Adverse events following immunization with oral poliovirus in Kinshasa, Democratic Republic of Congo: preliminary results.
abstract: OBJECTIVE
  We investigated the nature and frequency of adverse events following immunization (AEFI) associated with oral polio vaccines (OPV) in the general population in Kinshasa, Democratic Republic of Congo (DR Congo).
  
  
  METHODS
  The DR Congo National Pharmacovigilance Centre organized active AEFI surveillance during mass immunization campaigns for the general population from March to June 2011. A patient individual case safety report was used as a questionnaire and addressed to pupils and students from high schools and universities who had any adverse events after OPV administration. We used the preferred term from the WHO Adverse Reaction Terminology for AEFI designation. Here is presented the results of the second step of the mass immunization campaign.
  
  
  RESULTS
  A total of 767 patients reported AEFI during the second step. Sex distribution shows that 512 (66·8%) students were females, while 255 (33·2%) were males, giving a female/male ratio 2∶1. The average age was 16·8±5·19 years (ranged: 6-35·5 years). Each person reported a mean of 1·33±0·6 AEFI. The average AEFI onset duration was 1·74±1·16 days post-vaccination, ranging from 1 to 9 days. Headache (22·4%), abdominal pain (17·2%), fever (11·7%), diarrhea (9·9%), and asthenia (7·5%) were the common symptoms. Paralysis and asthma-like reactions were rare and serious adverse events in this study. The most affected systems were gastro-intestinal (33·5%) and nervous system (29·3%). Rechallenge was positive for 173 persons (22·6%).
  
  
  CONCLUSIONS
  OPV-related AEFIs are not uncommon, although it is under-reported. Active AEFI surveillance during mass immunization campaigns is very important and may help to detect rare and serious adverse events. Further investigation will be important to identify risk of AEFI with OPV in adults and is warranted to elucidate the cause of this association in the Congolese environment.
authors.forename: Didier
authors.initials: D
authors.lastname: Nzolo
authors.forename: Michel
authors.initials: M
authors.lastname: Ntetani Aloni
authors.forename: Thérèse
authors.initials: T
authors.lastname: Mpiempie Ngamasata
authors.forename: Bibiche
authors.initials: B
authors.lastname: Mvete Luemba
authors.forename: Sandrine
authors.initials: S
authors.lastname: Bazundama Marfeza
authors.forename: Mathilde
authors.initials: M
authors.lastname: Bothale Ekila
authors.forename: Célestin
authors.initials: C
authors.lastname: Ndosimao Nsibu
authors.forename: Narcisse
authors.initials: N
authors.lastname: Lutete Tona
mesh_terms: D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D002648:Child; D015023:Democratic Republic of the Congo; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D011051:Poliomyelitis / Q000517:prevention & control*; D017955:Poliovirus / Q000187:drug effects* / Q000276:immunology; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000009:adverse effects*; D011159:Population Surveillance; D011795:Surveys and Questionnaires
chemical_list: D011055:Poliovirus Vaccine, Oral
keywords: Adverse events following immunization,; Democratic Republic of Congo; Kinshasa,; Oral poliovirus,; Students,